Herbs (Global Traditional) · African
Yohimbe (Pausinystalia johimbe) (Pausinystalia johimbe)
Strong Evidencebotanical
Hermetica Superfood Encyclopedia
Yohimbe (Pausinystalia johimbe) contains yohimbine hydrochloride, an alpha-2 adrenergic receptor antagonist that improves blood flow and sexual function. Clinical studies demonstrate significant improvements in erectile dysfunction with nearly 3 times higher success rates versus placebo.
Yohimbe derives from the bark of the evergreen tree Pausinystalia johimbe (family Rubiaceae), native to western and central Africa, particularly Cameroon, Gabon, and the Congo. The active compounds are extracted via water or alcohol from the bark, yielding yohimbine hydrochloride as the primary standardized form used in clinical studies.
A 2022 systematic review and meta-analysis (PMC9612744) of 8 double-blind RCTs (n=460) found yohimbine superior to placebo for ED (OR=2.87, P<0.001). Key trials include a 1997 RCT (PMID: 9315493) showing 71% response rate vs 45% placebo, and a 1998 meta-analysis (PMID: 9649257) confirming efficacy (OR=3.85).
Clinically studied doses: 5.4-6 mg yohimbine HCl orally 3x daily (total 16.2-18 mg/day), equivalent to ~30 mg standardized bark extract (4-6% yohimbine), for 4-10 weeks. Some studies used up to 30 mg/day total yohimbine HCl. Consult a healthcare provider before starting any new supplement.
Yohimbe bark (Pausinystalia johimbe) is not consumed as a food source but rather as a pharmacologically active herbal preparation. Its value lies entirely in its bioactive alkaloid profile rather than macronutrient content. **Primary Bioactive Alkaloid:** • Yohimbine (indole alkaloid, alpha-2 adrenergic antagonist) — bark contains approximately 1–6% total alkaloids by dry weight, with yohimbine comprising roughly 10–15% of total alkaloid fraction, yielding approximately 1,000–15,000 mg/kg (0.1–1.5%) yohimbine in raw bark depending on source, age, and preparation method. Typical standardized extracts deliver 2–8 mg yohimbine per dose. **Secondary/Related Alkaloids:** • Corynanthine (rauwolscine/alpha-yohimbine) — approximately 0.1–0.5% of bark dry weight; acts as alpha-2 antagonist with slightly different receptor selectivity than yohimbine • Ajmalicine (raubasine) — approximately 0.05–0.3%; mild cerebrovascular vasodilator • Corynantheine — trace to 0.1%; mild alpha-adrenergic activity • Allo-yohimbine — trace amounts; stereoisomer of yohimbine with reduced potency • Dihydrocorynantheine — trace amounts • Pseudoyohimbine — trace amounts; weaker alpha-2 antagonism. **Minor Constituents:** • Tannins (condensed and hydrolyzable) — approximately 5–12% of bark dry weight; may affect GI absorption of co-consumed substances • Proanthocyanidins — variable amounts contributing to astringency • Plant sterols (beta-sitosterol, stigmasterol) — trace quantities • Saponins — minor amounts • Cellulose and lignin — bulk structural carbohydrates (not nutritionally relevant). **Mineral Content (trace, per gram of bark):** • Potassium, calcium, magnesium, iron, manganese — present in negligible nutritional quantities typical of tree bark matrices. **Bioavailability Notes:** • Oral bioavailability of yohimbine from raw bark is approximately 20–33%, with significant first-pass hepatic metabolism via CYP3A4 and CYP2D6 enzymes. • Peak plasma levels achieved in 45–90 minutes post-ingestion. • Half-life of yohimbine is approximately 0.5–2.5 hours (highly variable due to CYP2D6 polymorphisms — poor metabolizers may experience 3–5× higher plasma concentrations). • Tannins in raw bark may partially reduce alkaloid absorption compared to purified yohimbine HCl, though some evidence suggests the full-spectrum bark extract produces a more gradual absorption curve. • The presence of corynanthine and other alkaloids in whole bark may modulate the pharmacological profile compared to isolated yohimbine. • Alkaloid extraction efficiency increases substantially with ethanol-based preparations (70–90% ethanol) versus water decoctions (approximately 30–50% alkaloid recovery). • No significant macronutrient (protein, fat, carbohydrate), vitamin, or dietary fiber value — yohimbe bark is classified strictly as a pharmacological botanical, not a nutritional supplement.
Yohimbine hydrochloride blocks alpha-2 adrenergic receptors in peripheral blood vessels and genital tissue, reducing sympathetic nervous system activity that normally constricts blood flow. This antagonism increases nitric oxide availability and promotes vasodilation in penile arteries. Additionally, yohimbine may influence central nervous system pathways involved in sexual arousal and libido.
A meta-analysis of 8 randomized controlled trials involving 460 participants showed yohimbe supplementation provided 2.87 times greater odds of erectile dysfunction improvement compared to placebo. An RCT with 86 subjects demonstrated 71% response rate for enhanced sexual desire and arousal metrics. Polysomy studies indicate improved erection quality and rigidity with standardized yohimbine doses. Evidence quality is moderate, with most studies using 15-30mg yohimbine hydrochloride daily.
Common side effects include anxiety, elevated heart rate, hypertension, dizziness, and gastrointestinal upset. Yohimbe can interact dangerously with antidepressants (especially MAOIs), blood pressure medications, and stimulants, potentially causing hypertensive crisis. Contraindicated in individuals with heart disease, kidney disease, or psychiatric disorders. Pregnant and breastfeeding women should avoid use due to insufficient safety data.
